生产企业：Elevar Therapeutics, Inc.
Lirafugratinib (RLY-4008) is a potent, selective, oral small-molecule irreversible inhibitor of FGFR2, a receptor tyrosine kinase frequently altered in certain cancers. Its selective targeting of FGFR2 differentiates it from pan-FGFR inhibitors that broadly inhibit FGFR1, FGFR3 and/or FGFR4 in addition to FGFR2.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
